Cytokinetics Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference.
My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Cytokinetics, and presenting on behalf of the company, we have President and CEO, Robert Blum.
Robert, over to you.
Thank you Tess, and thank you to JP Morgan for inviting us again this year. This is a very important year for Cytokinetics, as I'll be elaborating as we are turning the page at cytokinetics after over 20 years and presenting at this conference to now a company that is commercial, considering that we just had our FDA approval of MYQORZO.
Thank you, we appreciate that, and here today we're going to talk about this monumental milestone and how we are prepared to meet the moment. I'll be making some forward-looking statements. I'll refer you to our SEC filings. For caveats to those statements, we don't undertake
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
